Literature DB >> 15550471

Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice.

Maddalena T Tilli1, Ronald Reiter, Annabell S Oh, Ralf T Henke, Kevin McDonnell, G Ian Gallicano, Priscilla A Furth, Anna Tate Riegel.   

Abstract

Amplified in breast cancer 1 (AIB1, also known as ACTR, SRC-3, RAC-3, TRAM-1, p/CIP) is a member of the p160 nuclear receptor coactivator family involved in transcriptional regulation of genes activated through steroid receptors, such as estrogen receptor alpha (ER(alpha)). The AIB1 gene and a more active N-terminally deleted isoform (AIB1-Delta3) are overexpressed in breast cancer. To determine the role of AIB1-Delta3 in breast cancer pathogenesis, we generated transgenic mice with human cytomegalovirus immediate early gene 1 (hCMVIE1) promoter-driven over-expression of human AIB1/ACTR-Delta3 (CMVAIB1/ACTR-Delta3 mice). AIB1/ACTR-Delta3 transgene mRNA expression was confirmed in CMV-AIB1/ACTR-Delta3 mammary glands by in situ hybridization. These mice demonstrated significantly increased mammary epithelial cell proliferation (P < 0.003), cyclin D1 expression (P = 0.002), IGF-I receptor protein expression (P = 0.026), mammary gland mass (P < 0.05), and altered expression of CCAAT/enhancer binding protein isoforms (P = 0.029). At 13 months of age, mammary ductal ectasia was found in CMV-AIB1/ACTR-Delta3 mice, but secondary and tertiary branching patterns were normal. There were no changes in the expression patterns of either ER(alpha) or Stat5a, a downstream mediator of prolactin signaling. Serum IGF-I levels were not altered in the transgenic mice. These data indicate that overexpression of the AIB1/ACTR-Delta3 isoform resulted in altered mammary epithelial cell growth. The observed changes in cell proliferation and gene expression are consistent with alterations in growth factor signaling that are thought to contribute to either initiation or progression of breast cancer. These results are consistent with the hypothesis that the N-terminally deleted isoform of AIB1 can play a role in breast cancer development and/or progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550471     DOI: 10.1210/me.2004-0106

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  21 in total

1.  Role of the nuclear receptor coactivator AIB1-Delta4 splice variant in the control of gene transcription.

Authors:  Christopher D Chien; Alexander Kirilyuk; Jordan V Li; Wentao Zhang; Tyler Lahusen; Marcel O Schmidt; Annabell S Oh; Anton Wellstein; Anna T Riegel
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

2.  Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.

Authors:  Tyler Lahusen; Mark Fereshteh; Annabell Oh; Anton Wellstein; Anna T Riegel
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  The activity and stability of the transcriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation.

Authors:  Hina Naeem; Donghang Cheng; Qingshi Zhao; Caroline Underhill; Marc Tini; Marc T Bedford; Joseph Torchia
Journal:  Mol Cell Biol       Date:  2006-10-16       Impact factor: 4.272

4.  Role of the nuclear receptor coactivator AIB1/SRC-3 in angiogenesis and wound healing.

Authors:  Maram Al-Otaiby; Elena Tassi; Marcel O Schmidt; Chris D Chien; Tabari Baker; Armando Ganoza Salas; Jianming Xu; Mary Furlong; Richard Schlegel; Anna T Riegel; Anton Wellstein
Journal:  Am J Pathol       Date:  2012-02-14       Impact factor: 4.307

Review 5.  The role of SRC-3 in human breast cancer.

Authors:  Ondrej Gojis; Bharath Rudraraju; Mihir Gudi; Katy Hogben; Sami Sousha; R Charles Coombes; Charles R Coombes; Susan Cleator; Carlo Palmieri
Journal:  Nat Rev Clin Oncol       Date:  2009-12-22       Impact factor: 66.675

Review 6.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

7.  Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.

Authors:  Annabell S Oh; John T Lahusen; Christopher D Chien; Mark P Fereshteh; Xiaolong Zhang; Sivanesan Dakshanamurthy; Jianming Xu; Benjamin L Kagan; Anton Wellstein; Anna T Riegel
Journal:  Mol Cell Biol       Date:  2008-09-02       Impact factor: 4.272

8.  Identification and characterization of PNRC splicing variants.

Authors:  Yuanzhong Wang; Yuping Li; Bin Chen; Yan Zhang; Guiyu Lou; Shiuan Chen; Dujin Zhou
Journal:  Gene       Date:  2008-07-25       Impact factor: 3.688

9.  The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.

Authors:  Mark P Fereshteh; Maddalena T Tilli; Sung Eun Kim; Jianming Xu; Bert W O'Malley; Anton Wellstein; Priscilla A Furth; Anna T Riegel
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

Review 10.  Steroid receptor coactivator-3 as a potential molecular target for cancer therapy.

Authors:  Jean Ching-Yi Tien; Jianming Xu
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.